GLP-1 Patient Pathway | Multimodal Obesity Care | GASTER control®
GLP-1, surgery, support: what if appetite regulation rested on several complementary pathways?
Where does GASTER control® fit within your GLP-1 journey — alongside, between, or after? Understand the multimodal logic of modern obesity care, and get in touch with our team.
Get in touchAppetite regulation involves several physiological pathways
Modern obesity care no longer rests on a single lever. GLP-1 therapies (Wegovy®, Ozempic®, Mounjaro®, Saxenda®) act through the hormonal pathway. Bariatric surgery acts through anatomical and mechanosensitive pathways. Dietary follow-up and behavioural support act through the cognitive and behavioural pathway. And the mechanosensorial pathway — the one explored by GASTER control® — is a complementary lever that can be articulated with the others within structured care.
GASTER control® is a CE Class I medical device for external abdominal compression, designed to support patients with overweight or obesity within a structured medical care pathway. It is a non-invasive medical belt that acts during meals on the mechanical perception of satiety.
This device is neither an alternative to GLP-1 therapies nor an alternative to bariatric surgery. It is approached as a mechanosensorial complement designed to be articulated with these treatments — alongside an active GLP-1 treatment, between treatment phases, or after a discontinuation. The decision to integrate it into your care pathway always belongs to an exchange with your physician.
Where are you in your GLP-1 pathway?
GASTER control® has been designed to articulate with GLP-1 therapies at several moments of the care journey — before, during, after, or alongside. Do you recognise your situation among the following? In every case, final clinical evaluation and orientation belong to an exchange with your physician.
You are considering a GLP-1 treatment
You are weighing whether to start a GLP-1 therapy, or wondering if other physiological levers can be explored first or in parallel. You want to make an informed decision in dialogue with your physician, with a clear understanding of the multimodal landscape.
Discuss this with our teamYou are on a GLP-1 treatment
You currently take Wegovy®, Ozempic®, Mounjaro® or Saxenda® as part of a medical weight management programme, and you are interested in complementary tools to support the durability of your gains.
Discuss multimodal optionsYou have discontinued a GLP-1 treatment
You have stopped your treatment for any reason (cost, side effects, clinical decision, supply disruption, end of prescribed duration), and you are observing or anticipating weight regain or the return of appetite.
Discuss the transitionYou are exploring multimodal pathways
You wish to combine several physiological levers — dietary follow-up, physical activity, medical follow-up, and a non-pharmacological mechanical complement — within a structured pathway, without relying on a single intervention.
Discuss your pathwayWhat GASTER control® is — and what it is not
To approach an informed medical discussion, it is helpful to frame both what this device is — and equally importantly, what it is not.
- A CE Class I medical device, designed for medical use
- A non-invasive, reversible external abdominal belt
- A complementary tool within a structured care pathway, under medical supervision
- Designed for long-term use, with no recurring monthly cost
- A device whose delivery involves an exchange with a healthcare professional
- An alternative to GLP-1 treatments or to bariatric surgery
- An over-the-counter product (its delivery is part of a medical pathway)
- A substitute for dietary, behavioural or medical follow-up
- A device intended for minors (under 18 years of age)
- The subject of any efficacy claim — current clinical data remain exploratory
The three physiological pathways of appetite regulation
Appetite is not regulated by a single mechanism. It results from the convergence of signals from several pathways, integrated by the brainstem. Modern obesity care increasingly leverages these pathways in combination, rather than in opposition.
Neuroendocrine modulation
Wegovy® · Ozempic® · Mounjaro® · Saxenda®
GLP-1 receptor agonists modulate appetite centrally, slow gastric emptying, and reduce reward signals. Their effect is suspensive — it depends on continued administration.
Surgical mechanosensitive change
Sleeve gastrectomy · Gastric bypass · Mini-bypass
Bariatric surgery acts through anatomical reorganisation of the digestive tract, altering gastric volume and the mechanosensitive signalling of satiety. Its effect is structural and long-term.
External abdominal compression
GASTER control® · Reusable medical belt
External abdominal compression acts on the perception of mechanical satiety signals during meals, without drug interaction nor surgical modification. Reversible and adjustable.
These three pathways are not in competition. They can be articulated within structured care, alongside dietary follow-up, behavioural support and physical activity — under medical supervision.
The patient journey in 3 steps
Here is what typically happens after you reach out to us. The exact steps may vary depending on your country of residence and the availability of partner healthcare professionals in your region.
Briefly describe your situation, your country of residence, and provide a way to contact you. No detailed medical data is requested at this stage.
Within 48 to 72 hours, we get in touch to discuss your situation, the availability of GASTER control® in your country, and the relevant next steps.
Where a partner network exists locally, an introduction can be arranged with a healthcare professional. Where no local network is yet in place, we keep you informed as availability expands.
Request a contact from our team
This form is open to adults across Europe and beyond who wish to learn more about GASTER control® and explore whether it can fit into their care pathway. Your interest is also a valuable signal that helps us evaluate where to extend the availability of the device next.
Your contact details will allow us to reach out within 48 to 72 hours for an initial informational exchange. No detailed medical data is collected at this stage — diagnosis and clinical orientation belong to your physician. Where GASTER control® is already available in your country through a partner network, you may be redirected to a local contact. Where it is not yet available, we keep you informed as availability expands.
Your questions, our answers
Can I use GASTER control® before starting a GLP-1 treatment?
Some patients explore non-pharmacological options before considering a GLP-1, either because they hesitate about a long-term medication, because they want to assess what they can do without first, or because their access to GLP-1 therapy is limited (eligibility criteria, cost, or treatment availability vary across countries). This is one of the clinical scenarios discussed during the medical exchange. The relevance of this approach for your specific situation can be assessed with your physician.
What is the point of a non-pharmacological tool when the GLP-1 is working?
Even during an effective GLP-1 treatment, two questions remain open: how to prepare for the moment when the treatment will be discontinued (cost, intolerance, end of prescribed duration), and how to consolidate behavioural habits during the therapeutic window. A mechanosensorial complement can support the development of eating habits that will persist beyond the medication, since the mechanical pathway of satiety is endogenous and does not stop with the treatment.
How is the sequence of tools determined?
The sequence depends on your clinical situation, your goals, and your preferences. A GLP-1 can be introduced first, then accompanied or relayed by a mechanosensorial complement. Conversely, a mechanosensorial complement can be introduced first, then combined with a GLP-1 if needed. This sequencing logic — articulating several pathways at the right moment for each patient — is at the heart of contemporary multimodal obesity care, and is discussed during the medical exchange with your physician.
How does the first contact take place?
After you submit the form, a member of our team reaches out by phone or email within 48 to 72 hours. This exchange is informational: its purpose is to introduce the device, understand your situation, and identify the relevant next steps depending on the availability of GASTER control® in your country. You remain free to take this further or not.
Is GASTER control® available in my country?
GASTER control® is currently distributed in France through our partner Lipoline, with a structured medical pathway. In other European countries and beyond, distribution is being progressively organised. By reaching out through the form, you allow us to assess interest in your country and direct you to the most relevant option — whether that means an immediate local introduction, or keeping you informed as availability expands.
What is the cost of the device?
The cost is communicated during the initial exchange with our team or our local distribution partner, as it depends on the prescription pathway and delivery modalities in your country. As an indication, GASTER control® operates on a one-time acquisition model: an initial investment, with no recurring monthly cost — unlike a pharmacological treatment, which requires monthly renewal.
Who can prescribe GASTER control®?
Delivery is part of a medical pathway. The exact category of prescribing healthcare professional depends on national regulations and on the distribution arrangement in your country. Nutritionists, endocrinologists, general practitioners informed about the device, and bariatric surgeons are typically involved in this orientation. Our team can help you identify a relevant pathway based on your situation and country.
Are there contraindications?
Like any medical device, GASTER control® has contraindications (pregnancy, abdominal hernia, recent history of abdominal surgery, severe digestive disorders, active eating disorders, certain cardiovascular conditions, minors, etc.). Individual evaluation belongs to a healthcare professional, who will review your situation during a clinical exchange.
Can I use it alongside my GLP-1 treatment?
GASTER control® acts through the mechanical pathway of satiety, without drug interaction or hormonal pathway involvement. Its use as a complement to a GLP-1 treatment, or as a relay during GLP-1 discontinuation, is among the clinical scenarios being explored. Final orientation always belongs to an exchange with your prescribing physician.
How is my data protected?
Your data is collected by GASTER Technology Limited (Malta) as data controller, solely for the purpose of this informational exchange. Where a local distribution partner is in place in your country, your contact details may be forwarded to that partner (e.g. Lipoline for France) under a GDPR-compliant subcontracting agreement. Your data is neither sold nor shared with third parties for commercial purposes. You may exercise your rights of access, rectification, objection and erasure at any time by contacting us. For more details, see our privacy policy.
Are you a healthcare professional?
Access detailed clinical documentation, mechanism of action and exploratory data associated with the device.
GASTER control® — GASTER Technology Limited, 5/1 Merchants Street, Valletta VLT 1171, Malta. Manufacturer registration EUDAMED SRN MT-MF-000047377. Exclusive distributor in France: Lipoline. Inquiries from other countries are welcome and handled directly by GASTER Technology.